Pharmacodynamic Mechanisms of Cicadae Periostracum in Parkinson's Disease: A Metabolomics-Based Study.

Mengmeng Li, Fuyu Xiong, Shifei Wu, Wenlong Wei, Hanze Wang, Yajun Qiao, Dean Guo

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mengmeng LiCollege of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun 130117, China.

Fuyu XiongCollege of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun 130117, China.

Shifei WuShanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Research Center of TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Wenlong WeiShanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Research Center of TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Hanze WangCollege of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun 130117, China.ORCID 0000-0002-2447-170X

Yajun QiaoShanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Research Center of TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Dean GuoCollege of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun 130117, China.

Funding

Qi-Huang Chief Scientist Program of National Administration of Traditional Chinese Medicine (2020). 2020

6 · The paper itself

Abstract

Cicadae Periostracum (CP) is a traditional Chinese animal-derived medicine with the potential to treat Parkinson's disease (PD). This study aims to explore the pharmacodynamic mechanisms of CP against PD-based on metabolomics technology and provide a theoretical basis for developing new anti-PD medicine. First, MPP

Indexed as

MetabolomicsNeuroprotective AgentsParkinson Diseasealpha-SynucleinAnimalsApoptosisCell Line, TumorDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLNeuronsalpha-SynucleinNeuroprotective AgentsCicadae Periostracummechanisms of actionmetabolomicsoxidative stressParkinson’s disease

Identifiers

PMID39859260

DOI10.3390/ijms26020544

PMCPMC11764672

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.